FDA-cleared profile

Myomics

Phantomics Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including heart and adjacent-vessel measurements; semi-automated machine-learning workflows are intended for adults and contribute to comprehensive diagnostic decision-making.

Clinical role
Measurement, segmentation and quantification
Images and patients
MRI · Heart/Cardiovascular
Key limitation
Keep in mind: Use only cardiac MR images from 3.0 T scanners. Semi-automated ML is intended for adults. Qualified cardiovascular-MR professionals must use results within comprehensive diagnostic assessment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including heart and adjacent-vessel measurements; semi-automated machine-learning workflows are intended for adults and contribute to comprehensive diagnostic decision-making.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Heart/Cardiovascular Input: DICOM cardiovascular MR images acquired at 3.0 T; AI modules cover native/post-contrast T1 maps, T2 maps, CINE, LGE PSIR, CINE RV and LGE magnitude.
  • Who uses it?Intended users: Qualified medical professionals experienced in examining and evaluating cardiovascular MR images
  • What does the software produce?Output: Semi-automatic endocardial/epicardial and myocardium segmentation across supported sequences, heart/adjacent-vessel measurements, image display, manual contouring and reports.
  • What is its most important limitation?Key limitation: Use only cardiac MR images from 3.0 T scanners. Semi-automated ML is intended for adults. Qualified cardiovascular-MR professionals must use results within comprehensive diagnostic assessment.

Clinical takeaway. Clinical role: Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including heart and adjacent-vessel measurements; semi-automated machine-learning workflows are intended for adults and contribute to comprehensive diagnostic decision-making.

Evidence takeaway. Evidence from the reviewed source record: Exact FDA technical validation is available. Stored cardiac-MR publications require full version review before application to K241922; one unrelated myosin paper is excluded.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including heart and adjacent-vessel measurements; semi-automated machine-learning workflows are intended for adults and contribute to comprehensive diagnostic decision-making.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Measurement, segmentation and quantification
  • Exact FDA submission
  • Checked 2026-09-05
Required input
DICOM cardiovascular MR images acquired at 3.0 T; AI modules cover native/post-contrast T1 maps, T2 maps, CINE, LGE PSIR, CINE RV and LGE magnitude.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Semi-automatic endocardial/epicardial and myocardium segmentation across supported sequences, heart/adjacent-vessel measurements, image display, manual contouring and reports.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Hospital or private-practice cardiovascular MR analysis; manual workflows have no stated population restriction, while semi-automated ML workflows are adult-only.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Qualified medical professionals experienced in examining and evaluating cardiovascular MR images
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Use only cardiac MR images from 3.0 T scanners. Semi-automated ML is intended for adults. Qualified cardiovascular-MR professionals must use results within comprehensive diagnostic assessment.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Exact FDA technical validation is available. Stored cardiac-MR publications require full version review before application to K241922; one unrelated myosin paper is excluded.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Exact FDA technical validation is available. Stored cardiac-MR publications require full version review before application to K241922; one unrelated myosin paper is excluded.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Reviewed exact-submission evidence reports segmentation overlap, not a disease-detection sensitivity.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

A disease-detection specificity for this release was not established in the reviewed sources.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K241922 Myomics bench and AI-module validation

  • DesignManufacturer bench comparison with Myomics Q/cvi42 Auto and held-out testing of seven segmentation modules
  • Population728 module-level anonymized test cases across MR vendors; module denominators 92, 91, 109, 90, 77, 192 and 77
  • Scopeexact submission
  • Tested versionMyomics configuration submitted in K241922; numerical release unspecified
  • Samplen=728
  • IndependenceSponsor or vendor study

K241922

Sample size is the summed module-case count, not confirmed unique patients. All modules reportedly exceeded mean Dice 0.7; detailed estimates, confidence intervals and reference-annotation methods were not established.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM cardiovascular MR images acquired at 3.0 T; AI modules cover native/post-contrast T1 maps, T2 maps, CINE, LGE PSIR, CINE RV and LGE magnitude.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · FDA 510(k) K241922: Myomics

  2. Routing

    Source context, not route validation: DICOM-standard cardiovascular MR import, display and export, worklist functions, contour tools and reporting.

    Scope: Exact FDA submission. Local PACS, EHR, HL7/FHIR and interface-version compatibility are not established.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · FDA 510(k) K241922: Myomics

  3. AI processing

    Source context, not route validation: Stand-alone software application with a graphical interface, described for integration into hospital or private-practice environments.

    Scope: Exact FDA submission. The summary does not establish current hosting architecture, compute sizing, region or latency.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · FDA 510(k) K241922: Myomics

  4. Returned objects

    Source context, not route validation: Semi-automatic endocardial/epicardial and myocardium segmentation across supported sequences, heart/adjacent-vessel measurements, image display, manual contouring and reports.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · FDA 510(k) K241922: Myomics

  5. Viewer/worklist/report

    Unresolved route: Semi-automatic endocardial/epicardial and myocardium segmentation across supported sequences, heart/adjacent-vessel measurements, image display, manual contouring and reports.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · FDA 510(k) K241922: Myomics

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Stand-alone software application with a graphical interface, described for integration into hospital or private-practice environments.
  • Exact FDA submission
  • Checked 2026-09-05

The summary does not establish current hosting architecture, compute sizing, region or latency.

Integration
DICOM-standard cardiovascular MR import, display and export, worklist functions, contour tools and reporting.
  • Exact FDA submission
  • Checked 2026-09-05

Local PACS, EHR, HL7/FHIR and interface-version compatibility are not established.

Vendor product-family context

Phantomics identifies Myomics as its cardiac MRI analysis solution and describes use in domestic and international hospitals; official manufacturer contact is available for configuration requests.

product family · checked 2026-09-05

Official Korean manufacturer page reviewed. Its family deployment narrative does not specify the K241922 release or establish current interfaces, security or clinical performance.

DICOM analysis workflow

Stand-alone GUI supports cardiovascular MR import/display/export, manual contours and reporting.

exact submission · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241922
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-02-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
21Fields reviewed
11Source classes checked
3Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

All three stored titles/dates screened. PMID 33053464 concerns myosin VI and is unrelated. PMIDs 36447413 and 39841643 are relevant cardiac-MR leads, but metadata alone does not establish K241922 version linkage; neither is promoted. Live PMID 36447413 retrieval returned HTTP 429. No stored trials. The current discovery snapshot contains 3 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, literature index, trial registry, vendor product page, stored candidate metadata, stored recall candidates, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    No exact license amount, unit, term or implementation/support costs were established from the reviewed FDA and manufacturer material.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Phantomics Myomics reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact FDA submission

    Current data flow, access controls, retention, hosting and dated scoped security evidence remain unestablished.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    The FDA specifies experienced cardiovascular-MR users, but vendor onboarding, competency and support commitments are not established.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Editorial acceptance question: assess each supported MR sequence, manual corrections and failed segmentations locally; no vendor monitoring capability is verified.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K241922: Myomics

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinicalUse, modality, anatomy, implementationCapabilities, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Myomics model card (K241922)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Phantomics About Us: Myomics cardiac MRI product-family context

    Phantomics - Accessed 2026-09-05

    Scope: productFamily, currentCommercialContext

Research history

  1. K241922 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252084

AI4CMR v2.0

Ai4medimaging Medical Solutions S.A.

Authorized purpose: Cardiac MRI ventricular function and 2D phase-contrast flow quantification

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2026-02-11
FDA-cleared K223523

Sonic DL

GE Medical Systems,LLC (GE Healthcare)

Sonic DL is deep-learning MRI reconstruction for highly undersampled or accelerated cardiac acquisitions on compatible GE 1.5T and 3.0T MRI systems for pediatric and adult patients.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2023-05-30
FDA-cleared K183274

RTHawk, HeartVista Cardiac Package

HeartVista, Inc.

Accessory acquisition, reconstruction, and display of cardiovascular MR images on compatible 1.5T and 3T whole-body MRI systems for trained-physician interpretation.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2019-10-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history